Free to read · nothing for sale · no ads, no sponsors · funded by donation

Open Source Apothecary At Home

Open Source Apothecary At Home / The herbs

Ginkgo

The most studied herb for memory — and the one whose large trials failed. Worth learning precisely because it is the clearest case of a promising observational signal that did not survive testing. — Ginkgo biloba

remedy
Ginkgo Ginkgo biloba — hand-drawn plate, stylised. Not for identification — use a field guide and verify with a second source before eating any wild plant.

Ginkgo biloba is the oldest living tree species and the most heavily researched plant for cognition, which makes it the best test case in the whole pharmacopoeia. The large randomised trials did not find that it prevents dementia or cognitive decline. Observational studies once suggested a protective association; when the question was put to properly powered randomised trials, the association did not hold — the standard explanation being that people taking ginkgo differed from those who did not.

What remains. Peripheral arterial disease and intermittent claudication have some positive trial evidence, as does tinnitus in some reviews, though both are inconsistent. Vertigo and "cerebral insufficiency" are traditional indications with weak support.

Why it is worth studying rather than skipping. Ginkgo is the cleanest illustration of two things this handbook returns to: an observational association is not a trial result, and a plausible mechanism — ginkgo does affect platelet function and blood flow — does not guarantee a clinical benefit. If you learn one plant to inoculate yourself against supplement marketing, learn this one.

The safety side is not trivial. Ginkgo affects platelets and has been associated with bleeding, including spontaneous haemorrhage and bleeding in people on anticoagulants. It is a genuine preoperative concern. Raw ginkgo seed is toxic; the leaf preparation is the medicinal part.

What the studies found

Meta-Analysis2026The Cochrane database of systematic reviews

Ginkgo biloba for cognitive impairment and dementia.

In people with cognitive complaints, we are unsure whether ginkgo improves global clinical status at six months, and it may be associated with an increased risk of AEs at three months.
PubMed 41641880 ↗
Meta-Analysis2025The world journal of biological psychiatry : the official journal of the World Federation of Societies of Biological Psychiatry

Ginkgo biloba extract EGb 761 is safe and effective in the treatment of mild dementia - a meta-analysis of patient subgroups in randomised controlled trials.

The meta-analysis demonstrates that patients with mild dementia benefit from EGb 761 in terms of cognition, activities of daily living, global assessment and quality of life.
PubMed 39895346 ↗
Meta-Analysis2024Medicine

Effect of long-term pharmacological treatments on Alzheimer disease: A systematic review and network meta-analysis.

In this network meta-analysis of studies of patients with AD and a follow-up period of at least 1 year, EGb 120 mg demonstrated cognitive benefits, while placebo posed the least harm for AD.
PubMed 39312316 ↗
Meta-Analysis2020Clinical neuropharmacology

Meta-analysis of Ginkgo biloba Preparation for the Treatment of Alzheimer's Disease.

Ginkgo biloba preparation has reliable efficacy of cognitive function and global clinical assessment and safety in the treatment of AD.
PubMed 32658034 ↗
Meta-Analysis2016The Cochrane database of systematic reviews

Antioxidant treatments for schizophrenia.

Although 22 trials could be included in this review, the evidence provided is limited and mostly not relevant to clinicians or consumers.
PubMed 26848926 ↗
Meta-Analysis2015Journal of Alzheimer's disease : JAD

Efficacy and adverse effects of ginkgo biloba for cognitive impairment and dementia: a systematic review and meta-analysis.

EGb761 at 240 mg/day is able to stabilize or slow decline in cognition, function, behavior, and global change at 22-26 weeks in cognitive impairment and dementia, especially for patients with neuropsychiatric symptoms.
PubMed 25114079 ↗

Growing it

Quick reference

| | | |---|---| | Life | Deciduous tree, extremely long-lived | | Hardiness | Fully hardy here (zone 4-9) — the constraint is space, not cold | | Size | 15-30 m. Grow it as a specimen, not a crop. | | Sex | Dioecious — buy a named male cultivar | | Soil | Tolerates most soils, including poor and compacted | | Light | Full sun to part shade | | Harvest | Leaf in autumn, as it yellows | | Yield reality | A tree takes 20+ years to give a useful leaf harvest |

The honest assessment. Buy the leaf. Ginkgo is a large, slow tree, and seed-grown plants are of unknown sex — the female produces the notoriously foul-smelling fruit. Named male clones ('Autumn Gold', 'Saratoga') are what you plant, and they are ornamental trees rather than a medicine crop. Growing your own leaf is a twenty-year project for a preparation that is cheap, standardised in clinical trials, and best bought from a supplier who states the ginkgo flavonoid and terpene lactone content — because that standardisation is what the trials used and it is not something you can reproduce at home.

Plant it because it is a beautiful tree and a remarkable survivor. Buy the extract.

See growing-woody-and-container-medicinals for tree planting in this climate.

Preparation

The form the trials used

  • Standardised leaf extract, specified as 24% ginkgo flavone glycosides and 6% terpene lactones
  • 120-240 mg a day in the positive trials; the dementia-prevention trials used 120 mg twice daily
  • Not raw leaf, tea, or a tincture of unspecified strength — those are not what was tested

If you grow your own leaf

  • Harvest as the leaves yellow in autumn, dry cool and dark
  • A leaf tea is traditional; note that the tea is not equivalent to the standardised extract
  • Do not use the seed or the fruit

Before any surgery or dental work

  • Stop ginkgo at least two weeks beforehand and tell the surgeon and anaesthetist

Cautions and interactions

When this is not a self-care problem — get help

Known interactions

Related

Sources

  1. Ginkgo biloba for cognitive impairment and dementia. The Cochrane database of systematic reviews 2026; doi:10.1002/14651858.CD003120.pub3 PubMed 41641880
  2. Ginkgo biloba extract EGb 761 is safe and effective in the treatment of mild dementia - a meta-analysis of patient subgroups in randomised controlled trials. The world journal of biological psychiatry : the official journal of the World Federation of Societies of Biological Psychiatry 2025; doi:10.1080/15622975.2024.2446830 PubMed 39895346
  3. Effect of long-term pharmacological treatments on Alzheimer disease: A systematic review and network meta-analysis. Medicine 2024; doi:10.1097/MD.0000000000039753 PubMed 39312316
  4. Meta-analysis of Ginkgo biloba Preparation for the Treatment of Alzheimer's Disease. Clinical neuropharmacology 2020; doi:10.1097/WNF.0000000000000394 PubMed 32658034
  5. Antioxidant treatments for schizophrenia. The Cochrane database of systematic reviews 2016; doi:10.1002/14651858.CD000209.pub2 PubMed 26848926
  6. Efficacy and adverse effects of ginkgo biloba for cognitive impairment and dementia: a systematic review and meta-analysis. Journal of Alzheimer's disease : JAD 2015; doi:10.3233/JAD-140837 PubMed 25114079